Applied DNA Sciences Reports Year End and Fiscal Fourth Quarter Results

Company To Hold Conference Call and Webcast Today, Thursday, December 28, 2017 at 4:30 PM EST. STONY BROOK, N.Y. - December 28, 2017 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), announced financial results for the full fiscal year and quarter ended September 30, 2017. Commenting on Applied DNA’s performance [...]

Applied DNA to Host Fourth Quarter and Fiscal 2017 Financial Results Conference Call on Thursday, December 28, 2017 at 4:30 PM ET

STONY BROOK, N.Y., December 26, 2017 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release results for the fourth quarter and fiscal 2017 ended September 30, 2017 after market close on Thursday, December 28, 2017. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern [...]

Applied DNA Announces $4.8 Million Registered Direct Offering of Common Stock

STONY BROOK, N.Y. – December 20, 2017 - Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”) today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 2,735,000 shares of common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a [...]

Molecular Tagging for Colorcon: A simple and seamless solution



APDN Announces Selected Preliminary Unaudited Fiscal 4th Quarter and Year End Results

STONY BROOK, N.Y. (December 15, 2017) - Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”) today announced selected preliminary unaudited financial results for the full fiscal year and quarter ended September 30, 2017. Preliminary (Unaudited) Fiscal 2017 Financial Results: Revenues increased 13% to $4.8 million as compared to $4.2 million in the prior fiscal year. [...]

Applied DNA to Present at the Imperial Capital 2017 Security Investor Conference on December 7 AT 9:00 AM ET

STONY BROOK, N.Y. (December 5, 2017) - Applied DNA Sciences, Inc. (NASDAQ: APDN; "Applied DNA", "the Company"), announced today that Dr. James Hayward, president & CEO, will present at Imperial Capital’s 2017 Security Investor Conference at the Intercontinental New York Barclay on Thursday, December 7 at 9:00 a.m. ET.  Dr. Hayward will present to an audience of investors [...]

Update on Pharmaceutical Market Opportunity

05 October 2017 Dear Investor: As an investor in Applied DNA Sciences you are likely aware of the potential applicability of our DNA molecular taggant platform to counter the growing threat from counterfeits in the global pharmaceutical industry. The World Health Organization estimates that 1% of the drug supply in developed countries is counterfeit — [...]

APDN to Present at 2017 Disruptive Growth Company Showcase

STONY BROOK, N.Y. September 21, 2017 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced that Dr. James Hayward, president & CEO, will present at the 2017 Disruptive Growth Company Showcase at the Grand Hyatt in New York City on Wednesday, September 27 at 2:30 p.m. ET. Dr. Hayward will present to an audience of investors [...]

APDN Files Form S-3 Registration Statement

STONY BROOK N.Y. (September 18, 2017) – Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has filed a Registration Statement with the Securities and Exchange Commission (the “Registration Statement”) with respect to the sale by certain selling security holders of common stock to be received upon exercise of warrants [...]

Applied DNA Reports Fiscal Third Quarter 2017 Financial Results

STONY BROOK, N.Y., August 10, 2017 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”, or "the Company"), announced financial results for the fiscal 2017 third quarter ended June 30, 2017. "We continued to make excellent progress in driving market adoption of our DNA technology platform in the fiscal third quarter while [...]